Overview


According to FutureWise analysis, the Organ-on-Chip Market in 2025 is US$170.23 million and is expected to reach US$2041.2 million by 2033, at a CAGR of 36.4%.The explosive growth of the Organ-on-Chip Market marks a transformative moment in the pharmaceutical industry, as it increasingly embraces cutting-edge, human-relevant testing platforms. These innovative solutions promise to dramatically speed up drug development processes while slashing costs. As global regulatory bodies warm up to alternative testing methods and the demand for personalized medicine continues to soar, the Organ-on-Chip Market is set to revolutionize preclinical research. By delivering advanced microfluidic systems that accurately replicate human organ functions like never before, this market is paving the way for a new era of medical breakthroughs.

The Organ-on-Chip Market is growing quickly as the pharmaceutical industry looks for better, more human-like testing methods that help cut down on drug development time and costs. With more regulatory agencies supporting new testing approaches and a rising interest in personalized medicine, these advanced microfluidic systems are set to change preclinical research by closely imitating how real human organs work.

This rapid growth is driven by the increasing demand for alternatives to animal testing and a greater adoption of personalized medicine. Technological advancements in microfluidics and 3D cell culture systems are also propelling innovation and commercialization in this field.

Organ-on-chip (OoC) technology is a recent development that benefits from the integration of tissue engineering and stem cells with microfluidics and the microfabrication of sensors and actuators. As an enhancement to current bioassays, OoC models aim to replicate aspects of human physiology and pathology, thereby shedding light on the mechanisms driving drug responses and the onset and progression of disease. OoC devices may offer more accurate model systems for the study of health and illness, according to growing data. Examples of evidence include showcases of vessels-on-chips, cancer-on-chips, kidney-on-chips, neurons, lung-on-chips, and ALS-on-chips. OoC models are already anticipated to be useful in drug discovery, efficacy, and toxicology, as well as in precision or even personalized medicine with the advent of patient-derived stem cells.

The OoC is a relatively new addition to the toolkit of model biological systems that are available to life science researchers to investigate many facets of human pathophysiology and illness. These systems span a range of physiological significance, with 3D cell cultures, organoids, and OoCs following 2D cell cultures in increasing relevance. Interestingly, using model species like mice and Drosophila to study physiology outperforms using synthetic tissue approaches. Unfortunately, this results in more challenging experiments because biological complexity rises with physiological relevance in model organisms. Despite major advancements in vivo imaging, in vivo physiological processes in mice, humans, and other mammals are often the least amenable to direct examination. The OoC could be seen as a bridging technology that allows for the use of complex cell cultures while also enabling better-tailored microenvironments to enhance the model.

FutureWise Market Research has published a report that provides an insightful analysis of Organ-on-Chip market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the Organ-on-Chip market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Altis Biosystems
  • AxoSim Inc.
  • Bi/ond
  • BiomimX SRL
  • Elveflow
  • Emulate Inc.
  • Hesperos
  • Hurel Corporation
  • Allevi Inc.
  • InSphero AG
  • Mimetas BV
  • Netri
  • Nortis Inc.
  • Tara Biosystems Inc.
  • TissUse GmbH

(Note: The list of major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Organ-on-Chip Market:

Emulate Inc.

  • In January 2024, Emulate partnered with Pfizer to co-develop organ-on-chip models for drug discovery and safety testing, with the goal of enhancing early-stage predictions of human responses.
  • Accepted into the FDA’s ISTAND Pilot Program, the Liver-Chip device became the first organ-on-chip platform evaluated in Investigational New Drug (IND) submissions for assessing drug-induced liver injury.

Mimetas BV

  • In August to October 2024, an enhanced kidney-on-a-chip model was launched under the OrganoPlate platform, allowing for more accurate modeling of nephrotoxicity and renal disease.
  • The ongoing expansion of high-throughput microfluidic tissue culture products into the North American and Asia-Pacific markets.

InSphero AG

  • In October 2024, an innovative next-gen liver-on-a-chip platform was unveiled, revolutionizing the way we assess drug-induced liver injury in preclinical settings. This cutting-edge technology promises to enhance our understanding and evaluation of liver responses to new medications like never before!

 

  • Valo Health acquired TARA Biosystems in April 2022, the business that developed a method for simulating 3D heart tissue. Valo intended to deploy TARA's cardiac tissue chips as part of an all-encompassing drug development solution focused on cardiovascular disease, driven by its Opal data platform.

The demand for organ-on-chips in drug screening, as well as the demand for lung- and kidney-based organ culture devices, is expected to drive the organ-on-chip market. Furthermore, the scarcity of donor organs and the availability of laboratory-engineered functional organs are expected to be significant advantages in meeting the growing demand for organ transplantation. However, the high cost of organ chip devices, as well as the development of organ-on-chip (OoC) technology, are expected to limit the market growth. Conversely, a significant increase in global healthcare expenditure has led to an increase in the size of the organ-on-chip market. The organ-on-chip market has a lot of potential in emerging economies. Demand for these products is expected to rise in the coming years due to an increase in the number of chronic diseases, high demand for organ transplantation, and an increase in animal testing for drug discovery. The apparatus can also be used to examine the impacts of environmental pollutants, the absorption of therapeutic aerosols, and the security and effectiveness of new medications. Lung-on-chip, which mimics the complex mechanical and biochemical properties of a human lung by combining microfabrication methods with contemporary tissue engineering, also offers a new in-vitro method of drug screening. Such vast application of Ooc is expected to boost the market growth during the forecast period.

By Organ Type

  • Lung-on-Chip
  • Heart-on-Chip
  • Liver-on-Chip
  • Intestine-on-Chip
  • Kidney-on-Chip

By Application 

  • Drug Discovery
  • Toxicology Research
  • Other Applications

By End-User 

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Other End Users

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasizes factors affecting the growth rate in the various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

Here’s a regional view of where the most progress is happening 

North America

  • In 2024, it dominates the OoC market with a revenue share of 42.8%. This market is home to many leading players, such as Emulate, Inc., CN Bio Innovations, and Hesperos, Inc. There is a strong focus on R&D collaborations, partnerships with the FDA, and academic-industry research programs.

Europe

  • Significant growth is driven by research institutions and start-ups, focusing on lung and heart-on-chip models, along with regulatory initiatives for non-animal testing. Examples of relevant companies include the UK-based OrganOx and the Germany-based TissUse GmbH.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. It dominates the organ-on-chip market due to factors including the accessibility of a wide range of services offered by key players, which include the custom creation of new chips with unique organ positioning and an increase in safety assessment on the different types of organ cells. Public and corporate institutions are making large investments in their research. For example, NIH projects that in 2021 and 2022, US$7,847 million and US$8,142 million will be spent on biotechnology research, respectively. This demonstrates a steady rise in research funding for biotechnology, which supports organ-on-chip research and propels the market during the forecast period. In addition to authorizations and launches in North America, numerous initiatives to provide organ-on-chip services also contribute to the market's expansion. For instance, Nikon Instruments Inc. in the United States announced in May 2022 that it would begin contract services for organ-on-a-chip imaging and analysis in an ideal way for research and development for drug discovery. Thus, these services broaden the application of organ-on-a-chip imaging, fostering commercial expansion in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Organ-on-Chip Market By Organ Type, By Application, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Targeted Antigen launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Organ-on-Chip Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Organ-on-Chip Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Organ-on-Chip Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Organ-on-Chip Market, By Organ Type Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Lung-on-Chip
        2. Heart-on-Chip
        3. Liver-on-Chip
        4. Intestine-on-Chip
        5. Kidney-on-Chip

  • 8.   Organ-on-Chip Market, By Application Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Drug Discovery
        2. Toxicology Research
        3. Other Applications

  • 9.   Organ-on-Chip Market, By End-User Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Pharmaceutical and Biotechnology Companies
        2. Academic and Research Institutes
        3. Other End Users

  • 10.   North America Organ-on-Chip Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 11.   Latin America Organ-on-Chip Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 12.   Europe Organ-on-Chip Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 13.   Asia Pacific Organ-on-Chip Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 14.   Middle East and Africa Organ-on-Chip Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Altis Biosystems
         1.1. Company Overview
         1.2. Prouct Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AxoSim Inc.
         2.1. Company Overview
         2.2. Prouct Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bi/ond
         3.1. Company Overview
         3.2. Prouct Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. BiomimX SRL
         4.1. Company Overview
         4.2. Prouct Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Elveflow
         5.1. Company Overview
         5.2. Prouct Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
         6. Emulate Inc.
        6.1. Company Overview
         6.2. Prouct Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Hesperos
         7.1. Company Overview
         7.2. Prouct Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Hurel Corporation
         8.1. Company Overview
         8.2. Prouct Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Allevi Inc.
         9.1. Company Overview
         9.2. Prouct Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. InSphero AG
         10.1. Company Overview
         10.2. Prouct Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Mimetas BV
         11.1. Company Overview
         11.2. Prouct Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Netri
         12.1. Company Overview
         12.2. Prouct Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Nortis Inc.
         13.1. Company Overview
         13.2. Prouct Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Tara Biosystems Inc.
         14.1. Company Overview
         14.2. Prouct Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. TissUse GmbH
         15.1. Company Overview
         15.2. Prouct Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

FAQ


An Organ-on-Chip is a microfluidic device that mimics the structure and function of human organs. These chips contain live cells that replicate the tissue environment, enabling drug testing, disease modeling, and toxicity studies without the exclusive reliance on animal models.

  • Growing demand for human-relevant drug testing is increasing.  
  • There is a rising emphasis on reducing animal testing due to ethical concerns.  
  • Advancements in microfluidics, stem cell technology, and 3D cell culture are noteworthy.  
  • Additionally, there is an expansion in pharmaceutical and biotechnology R&D.

Lung-on-Chip – The largest market share is approximately 34.8%.
Heart-on-Chip – The industry is expected to grow rapidly, with a projected compound annual growth rate (CAGR) of approximately 33.4%.
Liver, kidney, gut, and multi-organ chips – This is utilized for studies on toxicity and disease.
 

Related Market

Protein Chip Market

Read More

DNA and Gene Chip Market

Read More
Partner

Our Clients